Comparison · NCT04404361-0acbf10f
Pacritinib and SOC vs Placebo and SOC: Percentage of Participants With Progression to IMV and/or ECMO or Death
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pacritinib and SOC vs Placebo and SOC: Percentage of Participants With Progression to IMV and/or ECMO or Death. Trial comparisons, record NCT04404361-0acbf10f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04404361-0acbf10f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.263 | 0.186 | 0.357 | wilson | |
| Risk in group 2 | 0.248 | 0.174 | 0.34 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0151 | -0.105 | 0.135 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.06 | 0.661 | 1.7 | log | |
| Odds ratio, group 1 over group 2 | 1.08 | 0.573 | 2.05 | log | |
| Number needed to treat, for one more participant with the outcome on Pacritinib and SOC than on Placebo and SOC | 66.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pacritinib and SOC | Pacritinib 400 mg once daily \[QD\] on Day 1, then 200 mg twice daily \[BID\] from Day 2 to Day 14) + SOC~Pacritinib: 100 mg capsules | 26 | 99 | OG000 |
| Group 2 | Placebo and SOC | 4 capsules once daily \[QD\] on Day 1, then 2 capsules twice daily \[BID\] from Day 2 to Day 14) + SOC~Placebo: Placebo capsules matching pacritinib 100 mg capsules | 25 | 101 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Percentage of Participants With Progression to IMV and/or ECMO or Death
- Description
- The percentage is calculated as the number of patients who progress to IMV/ECMO or death divided by the total number of patients in the ITT population (n/N \* 100).
- Time frame
- Baseline to Day 28
- Population
Source ClinicalTrials.gov
Trial
- Title
- PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
- NCT number
- NCT04404361
- Phases
- PHASE2
- Conditions
- COVID19, COVID-19, COVID
- Interventions
- Pacritinib, Placebo
- Lead sponsor
- CTI BioPharma
- Results first posted
- 2024-06-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04404361?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04404361-0acbf10f